REVB net incomeQ3 2026-$3.32M
REVB net income was -$3.32M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.91M a year earlier. For the full fiscal 2025 it was -$8.91M, compared with -$15.04M in fiscal 2024.
Revelation Biosciences Inc. (REVB) financials
For the twelve months ended Sep 30, 2026, Revelation Biosciences Inc. reported -$12.16M of net income.
- Net income, TTM
- -$12.16M
- Cash
- $9.12M
- Market cap
- $2.8M
FY2019FY2025
FY2021FY2024
REVB revenue and earnings growth
REVB EPSQ3 2026-$5.92
REVB diluted EPS was -$5.92 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$23.95.
REVB free cash flowQ3 2026-$2.36M
REVB free cash flow was -$2.36M in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2024 it was -$18.34M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $4.06M | $3.55M | $4.15M | $5.38M | $6.91M | - | - |
| Selling, general and admin | $5.01M | $4.43M | $4.51M | $5.49M | $5.04M | $145.5K | - |
| Operating income | -$9.07M | -$7.98M | -$8.66M | -$10.86M | -$11.95M | - | - |
| Interest expense | - | - | - | - | $41.8K | - | - |
| Pre-tax income | - | - | - | - | - | -$1.63M | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | - | - |
| Net income | -$8.91M | -$15.04M | -$120.3K | -$10.83M | -$11.99M | -$1.63M | -$3.6K |
| EPS, basic | -$23.95 | -$1052.16 | -$101.28 | -$28646.40 | -$280160.00 | -$4482.56 | - |
| EPS, diluted | -$23.95 | -$1052.16 | -$101.28 | -$28646.40 | -$280160.00 | -$4482.56 | - |
| Diluted shares | 620,785 | 14,293 | 1,187.167 | 378.047 | 42.784 | 365.587 | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.70M | $6.50M | $11.99M | $5.25M | $1.27M | $4.49M | - |
| Short-term investments | - | - | - | - | - | $525.3K | - |
| Current assets | $10.81M | $6.57M | $12.15M | $5.41M | $1.91M | $651.3K | $22.7K |
| Total assets | $11.58M | $6.62M | $12.21M | $5.50M | $2.04M | $74.16M | $22.7K |
| Current liabilities | $2.00M | $1.91M | $5.56M | $4.45M | $2.14M | $3.43M | $26.3K |
| Total liabilities | $2.72M | $1.91M | $5.56M | $4.45M | $2.14M | $6.34M | $26.3K |
| Shareholders' equity | $8.86M | $4.71M | $6.65M | $1.05M | -$99.5K | $3.41M | -$3.6K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.27M | -$18.32M | -$7.29M | -$11.22M | -$11.09M | -$216.7K | - |
| Capital expenditures | - | $19.2K | - | - | $132.0K | - | - |
| Free cash flow | - | -$18.34M | - | - | -$11.22M | - | - |
| Investing cash flow | - | -$19.2K | - | - | -$132.0K | -$74.04M | - |
| Financing cash flow | $12.47M | $12.85M | $14.03M | $15.20M | $8.00M | $74.26M | - |
| Share repurchases | - | - | - | - | $35.50M | - | - |
| Stock-based compensation | $595.4K | $168.8K | $155.7K | $301.1K | $470.9K | - | - |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.51M | $1.92M | $1.38M | $964.2K | $922.9K | $1.32M | $858.8K | $605.5K | $831.0K | $1.39M | $717.6K | $1.06M |
| Selling, general and admin | $1.87M | $1.74M | $1.72M | $1.61M | $1.02M | $1.14M | $1.24M | $1.15M | $965.7K | $1.13M | $1.18M | $1.27M |
| Operating income | -$3.38M | -$3.66M | -$3.09M | -$2.57M | -$1.94M | -$2.46M | -$2.09M | -$1.75M | -$1.80M | -$2.52M | -$1.90M | -$2.33M |
| Income tax | $0 | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.32M | -$3.32M | -$3.01M | -$2.51M | -$1.91M | -$2.44M | -$2.05M | -$1.73M | -$2.24M | -$8.39M | -$2.68M | -$2.20M |
| EPS, basic | -$5.92 | -$0.87 | -$2.71 | - | -$49.51 | -$28.04 | -$25.34 | - | -$481.80 | -$2955.24 | -$472.44 | - |
| EPS, diluted | -$5.92 | -$0.87 | -$2.71 | - | -$49.51 | -$28.04 | -$25.34 | - | -$481.80 | -$2955.24 | -$472.44 | - |
| Diluted shares | 559,596 | 3.8M | 3.2M | - | 94,455 | 200,668 | 80,943 | - | 4,652.667 | 2,838.917 | 5,676.25 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $9.12M | $11.48M | $14.11M | $10.70M | $12.71M | $5.17M | $3.70M | $6.50M | $6.54M | $12.07M | $14.55M | $11.99M |
| Current assets | $9.27M | $11.68M | $14.21M | $10.81M | $12.83M | $5.36M | $3.93M | $6.57M | $6.66M | $12.20M | $14.62M | $12.15M |
| Total assets | $10.02M | $12.50M | $15.04M | $11.58M | $12.86M | $5.40M | $3.97M | $6.62M | $6.74M | $12.27M | $14.70M | $12.21M |
| Current liabilities | $2.33M | $1.88M | $1.42M | $2.00M | $1.85M | $1.57M | $1.09M | $1.91M | $4.07M | $11.13M | $5.23M | $5.56M |
| Total liabilities | $2.79M | $2.43M | $2.06M | $2.72M | $1.85M | $1.57M | $1.09M | $1.91M | $4.07M | $11.13M | $5.23M | $5.56M |
| Shareholders' equity | $7.23M | $10.07M | $12.99M | $8.86M | $11.00M | $3.83M | $2.88M | $4.71M | $2.67M | $1.14M | $9.47M | $6.65M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.36M | -$2.56M | -$3.21M | -$1.97M | -$1.59M | -$1.92M | -$2.79M | -$3.75M | -$9.26M | -$2.48M | -$2.84M | -$2.00M |
| Capital expenditures | $0 | $39.6K | $71.9K | - | - | - | - | -$17.7K | $17.7K | $0 | $19.2K | - |
| Free cash flow | -$2.36M | -$2.60M | -$3.29M | - | - | - | - | -$3.77M | -$9.27M | -$2.48M | -$2.86M | - |
| Investing cash flow | $0 | -$39.6K | -$71.9K | - | - | - | - | $17.7K | -$17.7K | $0 | -$19.2K | - |
| Financing cash flow | $0 | -$33.8K | $6.70M | -$41.2K | $9.12M | - | - | $3.69M | $3.74M | $0 | $5.42M | $0 |
| Stock-based compensation | $482.2K | $401.4K | $471.0K | $370.2K | $874 | $873 | $223.5K | $72.6K | $32.1K | $32.1K | $32.1K | $32.1K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.98 | 6.21 | 10.02 | 5.41 | 6.92 | 3.42 | 3.61 | 3.43 | 1.64 | 1.10 | 2.80 | 2.18 |
Source: XBRL data Revelation Biosciences Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 3-for-103, first reported Aug 11, 2023; 1-for-16, first reported Mar 6, 2025; 1-for-12, first reported Feb 26, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
REVB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| REVB | - | - | -$12.16M | - | $2.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
REVB FAQ
4 questionsIs REVB profitable?
No. Revelation Biosciences Inc. reported a net loss of $12.16M for the twelve months ended Sep 30, 2026.How much cash and debt does REVB have?
Revelation Biosciences Inc. reported $9.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did REVB last report financial results?
The latest statements here come from Revelation Biosciences Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this REVB financial data come from?
Quantisnow builds these statements from the structured XBRL data Revelation Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.